Download APIFINY® Prostate Cancer Risk Assessment Lower Risk Higher

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Prostate-specific antigen wikipedia, lookup

Transcript
Information for
Healthcare Professionals
The only cancer specific, non-PSA blood test that may aid clinicians
in the assessment of risk for the presence of prostate cancer.
®
APIFINY Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
Copyright © 2008-2016, Armune BioScience, Inc.
The only cancer specific, non-PSA blood test that may aid clinicians in
the assessment of risk for the presence of prostate cancer.
What is APIFINY®?
• APIFINY® is a cancer specific blood test that measures biological
markers known to be associated with an immune system response
to prostate cancer.
• APIFINY measures eight autoantibodies released by the
immune system in response to the presence of prostate cancer.1
• APIFINY autoantibodies were discovered by research conducted
at the University of Michigan under the direction of Arul
Chinnaiyan, MD, PhD.2
• APIFINY does NOT rely on PSA or a calculation based on
various forms of PSA.
• APIFINY is offered as a laboratory service available only to
healthcare providers to enable improved risk assessment for the
presence of prostate cancer in patients presenting with a PSA
>2.5 ng/ml or other high risk factors.
• APIFINY is offered by Armune BioScience in its CLIA regulated
laboratory located in Ann Arbor, MI. The test is used for clinical
purposes. It has not been cleared or approved by the FDA.
When should I order APIFINY?
• APIFINY may be used in men who have an elevated PSA
(>2.5 ng/ml) and are considering a prostate biopsy.
Why should I order APIFINY?
• APIFINY measures cancer specific biological markers that may
provide you with additional insight to support a clinical decision.
• In most cases, you already have the patient’s age, PSA level,
DRE result, and personal and family health history.
• Order APIFINY when additional, unique biological information
may help to make a more informed clinical decision.
1. Translational Oncology, 2015; 8, 106-111
2. New England Journal of Medicine, 2005; 353:1224-1235
®
APIFINY Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
How do I interpret an APIFINY Score?
APIFINY, combined with existing patient health information and your
clinical experience, may aid in the assessment of prostate cancer risk.
Interpretation of Results for Lower Risk Patients:
“In the most recent peer-reviewed published study on
APIFINY,1 approximately 9 out of 10 men like you, with a
score of less than 59, were cancer free.”
Interpretation of Results for Higher Risk Patients:
“In the most recent peer-reviewed published study on
APIFINY,1 approximately 1 out of 3 men like you, with a score of
59 or above, had prostate cancer. You may be at higher risk.”
Order APIFINY
Test Kits today!
®
®
APIFINY Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
The only cancer specific, non-PSA blood test that may aid clinicians in
the assessment of risk for the presence of prostate cancer.
Armune BioScience, Inc.
401 West Morgan Road
Ann Arbor, MI 48108
Toll Free Helpline: 844-427-6863
www.armune.com
APIFINY® is performed in the Armune BioScience high-complexity CLIA laboratory.
MM-004 Rev.05 03/16